“It is unclear how the IRA will be implemented. We further cannot predict with certainty what impact the IRA or any other federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition. There may be additional Congressional and administrative efforts to address drug pricing.”
All entries for: Sage Therapeutics
November 7, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic
August 7, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic
May 2, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic
November 8, 2022
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Concerns on Impact to Commercial Market & Development Decisions: “These risks as to pricing may further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if the pricing of any of our products are the subject of Medicare price negotiations. As a result, these risks may also impact the development decisions we make with respect to our products.”
Disease Area: Neurological Diseases
Drug Type: Biologic